DE60204620D1 - Nasenspray enthaltend Ondansetron-hydrochlorid - Google Patents

Nasenspray enthaltend Ondansetron-hydrochlorid

Info

Publication number
DE60204620D1
DE60204620D1 DE60204620T DE60204620T DE60204620D1 DE 60204620 D1 DE60204620 D1 DE 60204620D1 DE 60204620 T DE60204620 T DE 60204620T DE 60204620 T DE60204620 T DE 60204620T DE 60204620 D1 DE60204620 D1 DE 60204620D1
Authority
DE
Germany
Prior art keywords
weight
antiemetic
ondansetron hydrochloride
cyclodextrin
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60204620T
Other languages
English (en)
Other versions
DE60204620T2 (de
Inventor
Jin Auh
Chang Hwan Kim
In Koo Chun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ahn Gook Pharmaceutical Co Ltd
Original Assignee
Ahn Gook Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2002-0001758A external-priority patent/KR100434390B1/ko
Application filed by Ahn Gook Pharmaceutical Co Ltd filed Critical Ahn Gook Pharmaceutical Co Ltd
Publication of DE60204620D1 publication Critical patent/DE60204620D1/de
Application granted granted Critical
Publication of DE60204620T2 publication Critical patent/DE60204620T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60204620T 2001-04-20 2002-04-17 Nasenspray enthaltend Ondansetronhydrochlorid Expired - Lifetime DE60204620T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR2001021573 2001-04-20
KR20010021573 2001-04-20
KR2002001758 2002-01-11
KR10-2002-0001758A KR100434390B1 (ko) 2001-04-20 2002-01-11 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카바졸-4-온을 유효성분으로 하는 비강분무용조성물

Publications (2)

Publication Number Publication Date
DE60204620D1 true DE60204620D1 (de) 2005-07-21
DE60204620T2 DE60204620T2 (de) 2006-05-11

Family

ID=36217590

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60204620T Expired - Lifetime DE60204620T2 (de) 2001-04-20 2002-04-17 Nasenspray enthaltend Ondansetronhydrochlorid

Country Status (6)

Country Link
US (1) US20030044356A1 (de)
EP (1) EP1250925B1 (de)
JP (1) JP4152118B2 (de)
AT (1) ATE297730T1 (de)
DE (1) DE60204620T2 (de)
ES (1) ES2244726T3 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328186D0 (en) * 2003-12-05 2004-01-07 West Pharm Serv Drug Res Ltd Intranasal compositions
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
US20060045850A1 (en) * 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
BRPI0806633A2 (pt) * 2007-01-17 2011-09-06 Devirex Ag composição em gel, composição em spray, composição em gel nasal, composição de bálsamo labial, composição emulsificada, composição farmacêutica ou cosmética para aplicação em um local onda há uma infecção viral primária ativa ou um local conhecido que exibe uma infecção viral recorrente
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
ES2664599T3 (es) * 2009-05-20 2018-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistas del receptor 5-HT3 de serotonina para uso en el tratamiento de trastornos vestibulares lesionales
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
DK2747561T3 (en) * 2011-08-25 2018-08-06 Evoke Pharma Inc TREATMENT OF SYMPTOMS ASSOCIATED WITH FEMALE GASTROPARESIS
EP2759290B1 (de) 2013-01-24 2019-11-06 Merz Pharma GmbH & Co. KGaA Sprühbare flüssige zubereitung zur nasalen anwendung mit erhöhter lokaler verweilzeit
DE202013000748U1 (de) 2013-01-24 2013-02-19 Merz Pharma Gmbh & Co. Kgaa Sprühbare flüssige Zubereitung zur insbesondere nasalen Anwendung mit erhöhter lokaler Verweilzeit
DE102013001151A1 (de) 2013-01-24 2014-07-24 Merz Pharma Gmbh & Co. Kgaa Sprühbare flüssige Zubereitung zur insbesondere nasalen Anwendung mit erhöhter lokaler Verweilzeit
US9050325B2 (en) * 2013-04-08 2015-06-09 Abdul Zahir Ondansetron nasal spray composition
JP6634034B2 (ja) * 2014-06-25 2020-01-22 シネルジア・バイオ・サイエンシーズ・プライベイト・リミテッドＳｙｎｅｒｇｉａ Ｂｉｏ Ｓｃｉｅｎｃｅｓ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 医薬水中油型ナノエマルジョン
WO2016118540A1 (en) * 2015-01-20 2016-07-28 Xoc Pharmaceuticals, Inc. Treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or emesis
NZ747201A (en) 2016-04-14 2023-02-24 Sensorion (+)-azasetron for use in the treatment of ear disorders
WO2018112061A1 (en) 2016-12-15 2018-06-21 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
CN108066774B (zh) * 2018-01-11 2023-04-18 比卡生物科技（广州）有限公司 一种注射用卡巴他赛组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5688955A (en) * 1996-03-08 1997-11-18 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US6548082B1 (en) * 1999-03-01 2003-04-15 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
EP1185246A1 (de) * 1999-06-02 2002-03-13 Klöcker, Norbert, Dr.med. Pharmazeutische zusammmensetzung zur nasalen anwendung von wasserunlöslichen und/oder schwer wasserlöslischen wirkstoffen
US6780825B2 (en) * 2001-02-06 2004-08-24 Playtex Products, Inc. Cleansing compositions with milk protein and aromatherapy

Also Published As

Publication number Publication date
JP4152118B2 (ja) 2008-09-17
JP2002356424A (ja) 2002-12-13
US20030044356A1 (en) 2003-03-06
EP1250925A2 (de) 2002-10-23
ATE297730T1 (de) 2005-07-15
ES2244726T3 (es) 2005-12-16
EP1250925A3 (de) 2003-11-26
EP1250925B1 (de) 2005-06-15
DE60204620T2 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
DE60204620D1 (de) Nasenspray enthaltend Ondansetron-hydrochlorid
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
MXPA04000226A (es) Composiciones generadoras de mousse que contienen agentes de amonio cuaternario.
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
WO2006118948A3 (en) Therapeutic compositions
NO2010023I1 (no) Vernakalant eller et solvat eller farmasøytisk akseptabelt salt derav, herunder inkludert vernakalanthydroklorid
PT1257260E (pt) Formulacao de po
BR0003365A (pt) Composições farmacêuticas
ATE331517T1 (de) Pharmazeutische zusammenstellungen
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
JP2001187728A (ja) 眼科用組成物
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
RS50046B (sr) Farmaceutske kompozicije tizoksanida i nitazoksanida
PT1230236E (pt) Composto com propriedades de libertacao de hormonas de crescimento
PT992509E (pt) Novos derivados macrolidos
JP3846537B2 (ja) コンタクトレンズ用装着液
ATE528009T1 (de) Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten
ATE497764T1 (de) Perkutane absorptionszubereitungen mit 3-methyl-1-phenyl-2-pyrazolin-5-on
TW201720450A (zh) 眼科組成物
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
JP5092138B2 (ja) コンタクトレンズ装着液
BR0011845A (pt) Complexo farmacêutico
JP5673721B2 (ja) コンタクトレンズ装着液

Legal Events

Date Code Title Description
8364 No opposition during term of opposition